J Korean Neuropsychiatr Assoc.
2007 Nov;46(6):603-609.
Korean Medication Algorithm for Depressive Disorder 2006 (III): Major Depressive Episode with Psychotic Feature
- Affiliations
-
- 1Department of Neuropsychiatry and Stress Research Institute, Inje University College of Medicine, Inje University Seoul Paik Hospital, Seoul, Korea.
- 2Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
- 3Department of Psychiatry, College of Medicine, Konkuk University, Chungju, Korea.
- 4Department of Neuropsychiatry, College of Medicine, Chung-Ang University, Seoul, Korea.
- 5Department of Psychiatry, Hallym University , College of Medicine, Anyang, Korea.
- 6Department of Psychiatry, Hanmaeum Hospital, Seoul, Korea.
- 7Department of Neuropsychiatry, College of Medicine, Wonkwang University, Iksan, Korea.
- 8Department of Psychiatry, St. Andrew's Neuropsychiatry Hospital, Icheon, Korea.
- 9Department of Psychiatry, College of Medicine, University of Ulsan, Seoul, Korea.
- 10Korean College of Neuropsychopharmacology, Korean Society for Depressive and Bipolar Disorders and Korean Academy of Schizophrenia, Seoul, Korea.
Abstract
OBJECTIVES
Since the publication of Korean Medication Algorithm Project for Major Depressive Disorder (KMAP-MD) in 2002, there has been a substantial need for a revision due to rapid progress in the pharmacological management of depressive disorder. We revised KMAP-MD 2002 and developed the Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) 2006.
METHODS
We developed a questionniare for surveying the opinion of experts on pharmacotherapy of depressive disorder. The questionnaire consisted of 4 parts; 1) treatment of non-psychotic depressive disorder, 2) treatment of psychotic depressive disorder, 3) treatment according to clinical subtypes and drugs choice considering adverse effects, and 4) treatment of depressive disorder in women. The questionnaire was completed by the review committee consisting of 101 experienced Korean psychiatrists. It is composed of 22 questions, and each question includes 54 sub-items. We classified the expert opinion to 3 categories (the first-line, the second-line, or the third-line) by Chi2-test.
RESULTS
For depressive disorder with psychotic features, most reviewers prefer the combination of antidepressant and atypical antipsychotics. Electroconvulsive therapy and the combination of antidepressant and typical antipsychotics were the second-line treatment. Among antidepressants, venlafaxine was the most preferred, and SSRI and mirtazapine followed. Among atypical antipsychotics, quetiapine, risperidone and olanzapine were the most preferred, in this order. In patients who have no response to the first-line treatment, many reviewers recommended switching to another antidepressant or adding another atypical antipsychotics.
CONCLUSION
For severe depressive disorder with psychotic features, the combination of antidepressant and atypical antipsychotics was preferred for the first-line treatment. These results suggest that the medication strategies of depressive disorder are rapidly changing and reflects the recent studies and clinical experiences.